Were or are you an early stage breast cancer patient who has accessed a Gene Expression Profiling test in Ontario, such as Oncotype Dx or EndoPredict? If so, we would like to conduct a brief telephone interview with you.
CCSN is preparing a patient evidence submission on Gene Expression Profiling testing to Health Quality Ontario (HQO), which is currently conducting a health technology assessment for early invasive breast cancer. Your experience with a Gene Expression Profiling test will help to inform that submission and provide the expert committee at HQO with a valuable perspective as they prepare to issue their final funding recommendation for Gene Expression Profiling tests in Ontario.
If you have accessed a Gene Expression Profiling test, please contact Filomena at 416 809 2889 or email@example.com to schedule a quick telephone interview by no later than Monday, October 14, 2019. Sharing your lived experience may help to ensure access to Gene Expression Profiling tests for early stage breast cancer patients in Ontario.
Please note: patient privacy and confidentiality will be maintained at all times.